These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 8342072

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, Klein JL, Kapoor N, Harman GS, Avalos BR.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP.
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C, Gaziev D, Erer B, Ripalti M, Rapa S.
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A, Bureo E, Ortega JJ, Richard C, Olivé T, Maldonado MS, Madero L, Díaz MA.
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
    Saikia TK, Advani SH, Parikh PM, Bapna A, Somjee S, Mukhopadhyay A, Gopal R, Nair CN.
    J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
    [Abstract] [Full Text] [Related]

  • 10. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL, Avalos BR, Belt P, Taylor CA, Ezzone SA, Scholl MD, Fisher J, Young D, Copelan EA.
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [Abstract] [Full Text] [Related]

  • 11. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N.
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [Abstract] [Full Text] [Related]

  • 12. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, de Witte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A.
    Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
    [Abstract] [Full Text] [Related]

  • 13. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L.
    Med Clin (Barc); 1995 Nov 11; 105(16):605-11. PubMed ID: 8523939
    [Abstract] [Full Text] [Related]

  • 14. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
    Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR, Cooperative German Transplant Study Group.
    Eur J Haematol; 2006 Jan 11; 76(1):9-17. PubMed ID: 16343266
    [Abstract] [Full Text] [Related]

  • 15. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, Körbling M, Deisseroth AB, Champlin R.
    Bone Marrow Transplant; 1999 May 11; 23(10):977-81. PubMed ID: 10373061
    [Abstract] [Full Text] [Related]

  • 16. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, Takeshita A, Sao H, Kageyama S, Ueda R, Ohno R.
    Int J Hematol; 2000 Aug 11; 72(2):229-36. PubMed ID: 11039674
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.
    Natl Med J India; 2004 Aug 11; 17(2):71-3. PubMed ID: 15141598
    [Abstract] [Full Text] [Related]

  • 18. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
    Urban C, Schwinger W, Slavc I, Schmid C, Gamillscheg A, Lackner H, Hauer C, Pakisch B.
    Bone Marrow Transplant; 1990 May 11; 5(5):353-6. PubMed ID: 2190661
    [Abstract] [Full Text] [Related]

  • 19. Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen.
    Takami A, Chuhjo T, Nakao S.
    Haematologica; 2002 Jun 11; 87(6):659-61. PubMed ID: 12031925
    [No Abstract] [Full Text] [Related]

  • 20. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Dec 11; 22(11):1029-33. PubMed ID: 9877263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.